Definium Therapeutics (DFTX) Enterprise Value (2020 - 2026)
Definium Therapeutics (DFTX) reported Enterprise Value of -$368.1 million for Q1 2026, down 75.3% year-over-year from -$1.5 billion in Q1 2025, and up 10.01% on a QoQ basis from -$409.1 million in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Enterprise Value data on file, last reported at -$368.1 million in Q1 2026.
- Quarterly Enterprise Value fell 75.3% year-over-year to -$368.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$368.1 million (down 75.3% YoY) and the FY2025 annual result came in at -$409.1 million, down 50.67% from the prior year.
- Enterprise Value rose to -$368.1 million in Q1 2026 per DFTX's latest filing, from -$409.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$99.7 million in Q4 2023 and bottomed at -$409.1 million in Q4 2025.
- The 5-year median for Enterprise Value is -$196.0 million (2025), against an average of -$204.8 million.
- The widest annual swing landed in 2022, when Enterprise Value surged 32.66%; it then sank 172.31% in 2024.
- Tracing DFTX's Enterprise Value over 5 years: stood at -$131.7 million in 2022, then increased by 24.29% to -$99.7 million in 2023, then slumped by 172.31% to -$271.5 million in 2024, then slumped by 50.67% to -$409.1 million in 2025, then gained by 10.01% to -$368.1 million in 2026.
- Per Business Quant, the three latest DFTX Enterprise Value figures stand at -$368.1 million (Q1 2026), -$409.1 million (Q4 2025), and -$209.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -368.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -368.10 Mn |
| Dec 31, 2025 | -409.06 Mn |
| Sep 30, 2025 | -209.06 Mn |
| Jun 30, 2025 | -182.99 Mn |
| Mar 31, 2025 | -209.99 Mn |
| Dec 31, 2024 | -271.50 Mn |
| Sep 30, 2024 | -295.28 Mn |
| Jun 30, 2024 | -242.40 Mn |
| Mar 31, 2024 | -249.10 Mn |
| Dec 31, 2023 | -99.70 Mn |
| Sep 30, 2023 | -115.30 Mn |
| Jun 30, 2023 | -116.90 Mn |
| Mar 31, 2023 | -129.41 Mn |
| Dec 31, 2022 | -131.70 Mn |
| Sep 30, 2022 | -140.60 Mn |
| Jun 30, 2022 | -105.74 Mn |
| Sep 30, 2021 | -145.86 Mn |
| Jun 30, 2021 | -157.04 Mn |
| Mar 31, 2021 | -159.92 Mn |
| Dec 31, 2020 | -80.09 Mn |
| Sep 30, 2020 | -18.24 Mn |
| Jun 30, 2020 | -24.07 Mn |
| Mar 31, 2020 | -19.72 Mn |